304 related articles for article (PubMed ID: 30634453)
1. Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients.
Markiewicz A; Topa J; Nagel A; Skokowski J; Seroczynska B; Stokowy T; Welnicka-Jaskiewicz M; Zaczek AJ
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30634453
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential.
Markiewicz A; Książkiewicz M; Wełnicka-Jaśkiewicz M; Seroczyńska B; Skokowski J; Szade J; Żaczek AJ
PLoS One; 2014; 9(4):e93901. PubMed ID: 24709997
[TBL] [Abstract][Full Text] [Related]
3. Aggressive Phenotype of Cells Disseminated via Hematogenous and Lymphatic Route in Breast Cancer Patients.
Markiewicz A; Nagel A; Szade J; Majewska H; Skokowski J; Seroczynska B; Stokowy T; Welnicka-Jaskiewicz M; Zaczek AJ
Transl Oncol; 2018 Jun; 11(3):722-731. PubMed ID: 29660692
[TBL] [Abstract][Full Text] [Related]
4. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
5. Diversity of Epithelial-Mesenchymal Phenotypes in Circulating Tumour Cells from Prostate Cancer Patient-Derived Xenograft Models.
Hassan S; Blick T; Thompson EW; Williams ED
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34206049
[TBL] [Abstract][Full Text] [Related]
6. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
[TBL] [Abstract][Full Text] [Related]
7. Human-specific RNA analysis shows uncoupled epithelial-mesenchymal plasticity in circulating and disseminated tumour cells from human breast cancer xenografts.
Tachtsidis A; Le AV; Blick T; Gunasinghe D; De Sousa E; Waltham M; Dobrovic A; Thompson EW
Clin Exp Metastasis; 2019 Aug; 36(4):393-409. PubMed ID: 31190270
[TBL] [Abstract][Full Text] [Related]
8. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M
J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of Stemlike Circulating Tumor Cells in Invasive Breast Cancer.
Savelieva OE; Tashireva LA; Kaigorodova EV; Buzenkova AV; Mukhamedzhanov RK; Grigoryeva ES; Zavyalova MV; Tarabanovskaya NA; Cherdyntseva NV; Perelmuter VM
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316333
[TBL] [Abstract][Full Text] [Related]
10. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of mesenchymal markers expression-molecular profiles of cancer cells disseminated by lymphatic and hematogenous routes in breast cancer.
Markiewicz A; Książkiewicz M; Seroczyńska B; Skokowski J; Szade J; Wełnicka-Jaśkiewicz M; Zaczek AJ
Cancers (Basel); 2013 Nov; 5(4):1485-503. PubMed ID: 24217115
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer circulating tumor cells with mesenchymal features-an unreachable target?
Topa J; Grešner P; Żaczek AJ; Markiewicz A
Cell Mol Life Sci; 2022 Jan; 79(2):81. PubMed ID: 35048186
[TBL] [Abstract][Full Text] [Related]
14. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer.
Zhao R; Cai Z; Li S; Cheng Y; Gao H; Liu F; Wu S; Liu S; Dong Y; Zheng L; Zhang W; Wu X; Yao X
Oncotarget; 2017 Feb; 8(6):9293-9302. PubMed ID: 28030836
[TBL] [Abstract][Full Text] [Related]
16. Relationship Between Circulating Tumor Cells and Annexin A2 in Early Breast Cancer Patients.
Bystricky B; Cierna Z; Sieberova G; Janega P; Karaba M; Minarik G; Benca J; Sedlackova T; Jurisova S; Gronesova P; Pindak D; Macuch J; Mardiak J; Mego M
Anticancer Res; 2017 May; 37(5):2727-2734. PubMed ID: 28476852
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research.
Grover PK; Cummins AG; Price TJ; Roberts-Thomson IC; Hardingham JE
Ann Oncol; 2014 Aug; 25(8):1506-16. PubMed ID: 24651410
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer.
Guan X; Li C; Li Y; Wang J; Yi Z; Liu B; Chen H; Xu J; Qian H; Xu B; Ma F
Front Oncol; 2021; 11():602222. PubMed ID: 34150608
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
